Shares of Prothena Co. PLC (NASDAQ:PRTA) traded up 6.8% on Monday . The company traded as high as $14.67 and last traded at $14.25. 1,664,600 shares changed hands during mid-day trading, an increase of 137% from the average session volume of 703,752 shares. The stock had previously closed at $13.34.

A number of analysts have recently weighed in on the stock. BidaskClub downgraded shares of Prothena from a “buy” rating to a “hold” rating in a report on Saturday, September 8th. Zacks Investment Research upgraded shares of Prothena from a “sell” rating to a “hold” rating in a report on Friday, August 10th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $18.00 target price on shares of Prothena in a report on Wednesday, August 8th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $45.91.

The firm has a market capitalization of $531.42 million, a price-to-earnings ratio of -3.50 and a beta of 2.89.

Prothena (NASDAQ:PRTA) last released its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. Prothena had a negative net margin of 21,884.38% and a negative return on equity of 46.42%. The firm had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.22 million. analysts forecast that Prothena Co. PLC will post -4.17 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in PRTA. Aperio Group LLC purchased a new position in shares of Prothena during the 1st quarter worth about $222,000. Thrivent Financial for Lutherans boosted its stake in shares of Prothena by 127.9% during the 1st quarter. Thrivent Financial for Lutherans now owns 97,161 shares of the biotechnology company’s stock worth $3,567,000 after purchasing an additional 54,521 shares during the period. Employees Retirement System of Texas boosted its stake in shares of Prothena by 24.2% during the 1st quarter. Employees Retirement System of Texas now owns 113,000 shares of the biotechnology company’s stock worth $4,148,000 after purchasing an additional 22,000 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Prothena by 45.0% during the 1st quarter. Russell Investments Group Ltd. now owns 32,064 shares of the biotechnology company’s stock worth $1,177,000 after purchasing an additional 9,955 shares during the period. Finally, Woodford Investment Management Ltd boosted its stake in shares of Prothena by 0.3% during the 1st quarter. Woodford Investment Management Ltd now owns 11,557,614 shares of the biotechnology company’s stock worth $424,280,000 after purchasing an additional 29,000 shares during the period.

About Prothena (NASDAQ:PRTA)

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.

Featured Article: What strategies should day traders use to execute a trade?

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.